Genmab

Genmab A/S is a Danish-American biotechnology company. It was started in February 1999 by Florian Schönharting.

Genmab
Genmab A/S
Company typePublicly traded
OMX: GEN
IndustryBiotechnology
FoundedFebruary 1999
HeadquartersCopenhagen, Denmark
Key people
Jan van de Winkel (CEO)
ProductsDaratumumab (DARZALEX), Ofatumumab (Arzerra)
Total equity19,121 million DKK (2020)[1]
Websitewww.genmab.com

Genmab A/S is a Danish-American biotechnology company. It was started in February 1999 by Florian Schönharting.

The company's main office is in Copenhagen. It also has offices in Utrecht, Netherlands, and Princeton, USA. Genmab is listed on the Nasdaq Copenhagen stock exchange.[2][3]

Products

  • Ofatumumab (Arzerra): A medicine for certain types of leukemia.
  • Daratumumab (DARZALEX): A human CD38 antibody. The FDA gave this medicine "Breakthrough Therapy" status because it showed great promise in treating cancer patients who had no other options.[4]

History

Genmab started as a spinoff of an American company called Medarex. BankInvest provided the early money to start the business.[5]

In 2008, the CEO Lisa Natale Drakeman was the highest-paid director in Denmark, earning 28.6 million DKK.[6] However, the company faced hard times in 2009. They lost 965 million DKK[7] and had to lay off more than half of their workers (about 300 people).[8]

In 2010, Jan van de Winkel became the new CEO. Under his leadership, the company recovered its value. He has over 20 years of experience and has written over 300 scientific papers.[9]

References

  1. ↑ Annual Report 2021
  2. ↑ GEN, Genmab, (DK0010272202) - Nasdaq
  3. ↑ "About us". Archived from the original on 10. September 2013. Retrieved 16. September 2013. {{cite web}}: Check date values in: |access-date= and |archive-date= (help)
  4. ↑ "FDA grants Breakthrough Therapy status to daratumumab". Euroinvestor. 1. maj 2013. {{cite news}}: Check date values in: |date= (help)[permanent dead link]
  5. ↑ "FDA Grants GSK and Genmab's Arzerra Breakthrough Therapy Designation". GlobeNewswire. 13. september 2013. {{cite news}}: Check date values in: |date= (help)
  6. ↑ Kåre Pedersen (5. juni 2008). "EU countries want laws against high bonuses". Information. {{cite news}}: Check date values in: |date= (help)
  7. ↑ Ritzau (24. februar 2009). "Genmab hopes to cut losses in half". Information. {{cite news}}: Check date values in: |date= (help)
  8. ↑ "Genmab fires half of its employees". TV2. 5. november 2009. Archived from the original on 2009-11-15. Retrieved 2026-01-14. {{cite news}}: Check date values in: |date= (help)
  9. ↑ "Genmab - Jan van de Winkel". Archived from the original on 2016-08-15. Retrieved 14. juli 2016. {{cite web}}: Check date values in: |access-date= (help)

Other websites


Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.